Cell Migration and Cell Invasion Assay Market to USD 2.92 Bn by 2032

The global cell migration and cell invasion assay market size is expected to be worth USD 1.67 billion in 2025. It can touch a valuation of USD 2.92 billion by 2032. The market is anticipated to display a CAGR of 8.3% during the forecast period (2025-2032).  

The ongoing research in oncology and the alarming rise of cancer cases worldwide can induce the demand for cell migration and cell invasion assays. Studies of tumor immune microenvironments and personalized immunotherapies can drive the market growth significantly.

However, the high cost of assay kits and their unaffordability by smaller labs can limit the market growth.

The cell migration and cell invasion assay market is anticipated to soar owing to the strides in 3D cell cultures and development of tumor invasion models.

The understanding of altered pathways and metastatic transmission caused by cancerous cells can spur the cell migration and cell invasion assay market growth. Advances in cell migration and other techniques for detecting their presence can fuel the market growth. 3D printing of cell culture inserts and the shift from animal models can be sustainable for the market. This is illustrated by an initiative called the Alternative Methods Advancement Project (AMAP) by Charles River Laboratories in August 2024 for the ethical use of animal models.

The integration of 3D tumor invasion models with automated image analysis is expected to be a major catalyst for the market growth. The use of cell cultures by academic institutions and biopharmaceutical companies can drive the demand. For instance, the creation of chemotactic gradients in 3D cell cultures that have been used to mimic the brain tumor environment was published in the American Chemical Society on April 23, 2024. The gradients were directed for cell migration in a hydrogel-based open fluidic system.

Adherence to compliance standards by the U.S. Food & Drug Administration (FDA) and the European Union’s European Medicine Agency (EMA) are causing delays in the production of assay kits. The undefined potency testing for cell-based assays can cause delays in approvals or filings of new products.

Sphere Fluidics introduced its CytoSelect Cell Migration and Invasion Assay kits on December 10, 2024, designed to evaluate the invasive behavior of cells.